Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Tenax Therapeutics (NASDAQ: TENX) achieved randomization of 230 patients in the Phase 3 LEVEL study and expects topline results in Q3 2026. The company initiated global Phase 3 LEVEL-2 and opened an OLE study. USPTO issued a Notice of Allowance for subcutaneous levosimendan formulations. Cash was $97.6M at 12/31/2025, expected to fund operations through 2027. R&D and G&A expenses increased materially in 2025, contributing to a 2025 net loss of $52.6M versus $17.6M in 2024.
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026. The presentation is scheduled for March 10, 2026 at 2:20 p.m. ET with CEO Chris Giordano, CMO Stuart Rich, and CBO Douglas Randall.
A live and archived webcast will be available on the company’s investor relations webpage.
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
When: February 11, 2026 at 12:30 p.m. ET. Participants: Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer. A live and archived webcast will be available on the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported that a prespecified blinded sample size re-estimation (BSSR) for the Phase 3 LEVEL trial showed the study is powered at >90% to detect a 25-meter change in 6-minute walk distance (6MWD), with observed standard deviation in the first 150 randomized patients below the assumed 55 meters. Tenax confirmed no increase in target enrollment and reiterated that LEVEL enrollment is expected to complete in the first half of 2026, with topline data expected in the second half of 2026.
The company also initiated LEVEL-2, a global Phase 3 trial planning ~540 patients randomized 2:1 (TNX-103 vs placebo) with primary endpoint 6MWD at Week 26, selecting >100 sites across 15 countries and estimating enrollment completion by end of 2027. Tenax will open a global open-label extension to provide continued access to TNX-103.
Tenax Therapeutics (NASDAQ: TENX) will present at two investor conferences in early December 2025: a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 4:15 p.m. ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 11:30 a.m. ET.
Participants include Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer. Live and archived webcasts will be available from the company’s investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) reported Q3 2025 results and clinical updates on Nov 12, 2025. The company expects to enroll 230 patients in the Phase 3 LEVEL study in H1 2026 with topline data H2 2026, and remains on track to initiate the global LEVEL-2 registrational study in 2025 with >160 qualified sites across 15 countries. The European Patent Office issued an Intent to Grant a patent covering levosimendan for PH-HFpEF, with a term to Dec 2040 and possible SPC extension. Cash and equivalents were $99.4M at Sept 30, 2025, with runway through 2027. Q3 operating costs rose and net loss widened to $15.8M.
The company will host a virtual KOL call on Nov 13, 2025 at 4:30 p.m. ET.
Tenax Therapeutics (NASDAQ: TENX) will host a virtual KOL call on November 13, 2025 at 4:30 p.m. ET to discuss the PH-HFpEF treatment landscape and the late-stage program for TNX-103 (oral levosimendan).
Panelists include Tenax management and KOLs Barry A. Borlaug, M.D., and Sanjiv J. Shah, M.D. The company is advancing TNX-103 in two registrational Phase 3 studies, LEVEL (North American enrollment ongoing) and LEVEL-2 (global study on track to initiate in 2025). The call will be available live and archived via the company investor relations webpage; dial-in numbers are provided for U.S. and international callers.
Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company's presentation is a fireside chat on November 10, 2025 at 4:00 p.m. ET, featuring Chris Giordano, President & Chief Executive Officer, and Stuart Rich, M.D., Chief Medical Officer. A live webcast and archived replay will be available on the company's investor relations webpage.
Tenax Therapeutics (NASDAQ:TENX) announced that the European Patent Office (EPO) intends to grant a patent for the use of levosimendan, including TNX-103, in treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The patent will provide protection through December 2040, with potential for extension beyond.
The patent will cover multiple administration routes including oral, intravenous, inhaled, transdermal, and subcutaneous use, as well as levosimendan's active metabolites. This development comes as Tenax prepares to launch its LEVEL-2 Phase 3 study in Europe, expanding their global clinical trial presence.
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, will participate in the Cantor Global Healthcare Conference 2025. The company's presentation will take the format of a fireside chat featuring President & CEO Chris Giordano and Chief Medical Officer Dr. Stuart Rich.
The presentation is scheduled for September 4, 2025, at 10:20 a.m. ET in New York. Investors can access both the live and archived webcast through the company's investor relations webpage.